Medexus Pharmaceuticals Inc.

For fiscal Q1 2027, Medexus reported total net revenue of $28.6 million, up from $24.6 million in the prior-year period. Gross profit was $15.9 million versus $13.8 million; gross margin was 55.6% versus 56.0%; adjusted gross margin was 63.8% versus 65.5%; adjusted EBITDA was $4.7 million versus $3.4 million; operating income was $2.1 million versus $0.9 million; and net income was $0.5 million, consistent with last year. GRAFAPEX product-level net revenue was $4.9 million, and underlying patient demand was $4.8 million, up 23% sequentially from $3.9 million in Q4 2026 and 118% from $2.2 million in Q1 2026. Looking ahead, management reaffirmed GRAFAPEX product-level net revenue guidance of $30 million to $32 million for fiscal 2027, said the product could reach $100 million to $175 million within 5 years after launch, and expects meaningful operating cash flow in fiscal 2027.

Ken d’Entremont framed the quarter as validation of Medexus’ growth strategy, saying GRAFAPEX is performing in line with expectations and is becoming an increasingly important driver of the business. He emphasized strong commercial adoption, repeat ordering, supportive payer access, and continued traction in adult use, where the market opportunity is largest. He also pointed to UM171 cell therapy as a strategic fit with Trecondyv in Canada and said the company will keep investing in HSCT and adjacent areas.

Brendon Buschman focused on the financial durability of the portfolio and the economics of GRAFAPEX. He noted GRAFAPEX generated $4.9 million of product-level net revenue in the quarter versus $3.2 million of personnel and infrastructure investment, and said gross margin was 55.6% while adjusted gross margin was 63.8%, both down year over year mainly because Q1 2026 included a one-time royalty benefit. He said cash used by operating activities was $0.7 million, net debt was $20.9 million, and net debt to adjusted EBITDA was 1.18x; he also said the company expects meaningful operating cash flow in FY2027 and would be comfortable with leverage back in the 3x range given portfolio durability and confidence in GRAFAPEX.

Analysts focused heavily on GRAFAPEX’s trajectory, asking how the company gets from $4.9 million in Q1 to the full-year $30 million to $32 million target, how much of revenue is repeat orders, and what is driving the strong adoption. Management said most revenue is now coming from repeat hospital orders, that price has been strong with little to no discounting, and that leading indicators such as formulary listings, payer support, and first hospital use give them confidence. They also addressed wholesaler inventory, saying it was about one month at quarter-end, and clarified that the prior-year royalty revenue was a one-time item that did not recur in Q1 2027. On UM171, they said the next step is a meeting with Health Canada, likely in the fall, and on GRAFAPEX’s NTAP they said it has been confirmed to continue for another year.